A DTaP–IPV//PRP∼T vaccine (Pentaxim™): a review of 16 years’ clinical experience

References

• Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offit PA (Eds). Saunders Co., PA, USA 157–175 (2008).
   Google Scholar
• Edwards K, Decker M. Pertussis vaccines. In: Vaccines. 5th edition. Plotkin S, Orenstein W, Offit PA (Eds). Saunders Co., PA, USA 467–517 (2008).
   Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st Century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev.13(2), 302–317 (2000).
   PubMed Web of Science ®Google Scholar
• Vitek CR, Wharton M. Diptheria toxoid. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offit PA (Eds). Saunders Co., PA, USA 139–155 (2008).
   Google Scholar
• Wassilak SG, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offit PA (Eds). Saunders Co., PA, USA 139–155 (2008).
   Google Scholar
• Edwards KM, Decker MD. Combination vaccines: hopes and challenges. Pediatr. Infect. Dis. J.13(5), 805–839 (1994).
   Google Scholar
• Pichichero ME. New combination vaccines. Pediatr. Clin. North Am.47(2), 407–426 (2000).
   PubMed Web of Science ®Google Scholar
• Obaro SK, Palmer A. Vaccines for children: policies, politics and poverty. Vaccine21(13–14), 1423–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Andre FE, Booy R, Bock HL et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull. World Health Organ.86(2), 140–146 (2008).
   PubMed Web of Science ®Google Scholar
• Aristegui J, Usonis V, Coovadia H et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int. J. Infect. Dis.7(2), 143–151 (2003).
   PubMedGoogle Scholar
• Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J.20(11 Suppl.), S10–S18 (2001).
   PubMedGoogle Scholar
• Decker M, Bogaerts H, Edwards K. Combination vaccines. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offit PA (Eds). Saunders Co., PA, USA 1069–1101 (2008).
   Google Scholar
• Watt JP, Wolfson LJ, O’Brien KL et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet374(9693), 903–911 (2009).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diphtheria position paper. Wkly Epidemiol. Rec.81(3), 24–32 (2006).
   PubMedGoogle Scholar
• World Health Organization. Tetanus position paper. Wkly Epidemiol. Rec.81(20), 198–208 (2010).
   Google Scholar
• World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol. Rec.81(15), 137–144 (2006).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommended childhood immunization schedule – United States, 2001. MMWR50(1), 1–3 (2001).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses – worldwide, January 2006–August 2007. MMWR56(38), 996–1001 (2007).
   PubMedGoogle Scholar
• Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature434(7034), 699–700 (2005).
   PubMed Web of Science ®Google Scholar
• Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol.59, 587–635 (2005).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol. Rec.78(28), 241–252 (2003).
   PubMedGoogle Scholar
• World Health Organization. Vaccine-derived polioviruses – update. Wkly Epidemiol. Rec.81(42), 398–404 (2006).
   Google Scholar
• Vashishtha VM, Kalra A, John TJ, Thacker N, Agarwal RK. Recommendations of 2nd National Consultative Meeting of Indian Academy of Pediatrics (IAP) on polio eradication and improvement of routine immunization. Indian Pediatr.45(5), 367–378 (2008).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices. MMWR49, 1–22 (2000).
   PubMedGoogle Scholar
• Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine26(39), 4978–4983 (2008).
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics96(3 Pt 2), 557–566 (1995).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Deloria MA, Rennels MB et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics100(5), 772–788 (1997).
   PubMed Web of Science ®Google Scholar
• Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC. An economic evaluation of universal pertussis vaccination in Italy. Vaccine17(19), 2400–2409 (1999).
   Google Scholar
• Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch. Pediatr. Adolesc. Med.154(8), 797–803 (2000).
   PubMed Web of Science ®Google Scholar
• Tormans G, Van Doorslaer E, Van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur. J. Pediatr.157(5), 395–401 (1998).
   PubMed Web of Science ®Google Scholar
• Thisyakorn U, Montellano M, Ortiz E, Lane A. A review of hepatitis B vaccine administration schedules in infants. Presented at: 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 23–26 September 2010.
   Google Scholar
• Capeding MR, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP–IPV//PRP∼T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull. World Health Organ.86(6), 443–451 (2008).
   Google Scholar
• Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. Indian Pediatr.46(11), 975–982 (2009).
   Google Scholar
• Madhi SA, Cutland C, Jones S, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaP–IPV//PRP∼T booster vaccine in South African infants aged 18 to 19 months. Programs and Abstracts of the 26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa (2010).
   Google Scholar
• Madhi SA, Cutland C, Jones S, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa. S. Afr. Med. J.101, 126–131 (2011).
   PubMed Web of Science ®Google Scholar
• Kanra G, Silier T, Yurdakok K et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP–IPV//PRP–T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine18(9–10), 947–954 (1999).
   Google Scholar
• Li RC, Li FX, Li YP et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine29(10), 1913–1920 (2011).
   Google Scholar
• Langue J, David T, Roussel F, Pines E, Hoffenbach A. Safety and immunogenicity of DTaP–IPV and Act-Hib vaccines administered either combined or separately to infants at 2, 3, and 4 months of age. Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France (1997).
   Google Scholar
• Mallet E, Hoffenbach A, Salomon H, Blondeau C, Fritzell B. Primary immunization with combined, acellular DTaP–IPV–Act-HIB vaccine given at 2–3–4 or 2–4–6 months of age. Programs and Abstracts of the 14th European Societies for Paediatric Infectious Diseases. Elisnore, Denmark (1996) (Abstract 19).
   Google Scholar
• Reinert P, Boucher J, Pines E, Leroux MC, Hoffenbach A, Salomon H. Primary or booster immunization with DTaP–IPV vaccine administered either in combination or in association with Haemophilus influenzae type b vaccine (Act-Hib): a large-scale safety study. Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France (1997).
   Google Scholar
• Lagos R, Kotloff K, Hoffenbach A et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr. Infect. Dis. J.17(4), 294–304 (1998).
   PubMed Web of Science ®Google Scholar
• Mallet E, Fabre P, Pines E et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J.19(12), 1119–1127 (2000).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Selstam U et al. Safety and immunogenicity of a combined diphtheria–tetanus–acellular pertussis–inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2–4–6–13 or 3–5–12 months of age. Pediatr. Infect. Dis. J.17(11), 1026–1033 (1998).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr. Infect. Dis. J.21(6), 535–541 (2002).
   PubMed Web of Science ®Google Scholar
• Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Immunogenicity and safety of a DTaP–IPV//PRP–T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J. Trop. Med. Public Health40(2), 282–294 (2009).
   Google Scholar
• Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Southeast Asian J. Trop. Med. Public Health41(2), 450–462 (2010).
   Google Scholar
• Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics93(1), 37–43 (1994).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pertussis position paper. Wkly Epidemiol. Rec.85(40), 385–400 (2010).
   PubMedGoogle Scholar
• Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics112(5), e348 (2003).
   Google Scholar
• Collins CL, Salt P, McCarthy N et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine22(31–32), 4262–4269 (2004).
   PubMed Web of Science ®Google Scholar
• Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B. Persistence of antibodies at 5–6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5–6 years of age. Vaccine22(11–12), 1406–1414 (2004).
   PubMed Web of Science ®Google Scholar
• Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine22(11–12), 1415–1422 (2004).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol.17(7), 1055–1065 (2010).
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Trollfors B. Control of pertussis – lessons learnt from a 10-year surveillance programme in Sweden. Vaccine27(42), 5709–5718 (2009).
   PubMedGoogle Scholar
• Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol. Infect.137(1), 124–130 (2009).
   Google Scholar
• World Health Organization. Validation of neonatal tetanus elimination in selected states – India. Wkly Epidemiol. Rec.83(21), 185–192 (2008).
   PubMedGoogle Scholar
• Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum. Vaccin.4(5), 328–340 (2008).
   PubMed Web of Science ®Google Scholar
• Dutta A, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity and safety of a DTaP–IPV//PRP∼T booster vaccination at 18 to 19 months of age in Indian infants. Programs and Abstracts of the 3rd Asian Pacific Congress of Pediatrics. Shanghai, China (2009).
   Google Scholar
• Li RC, Li FX, Li YP et al. Antibody persistence at 18–20 months of age following primary vaccination of healthy infants with a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) and immunogenicity and safety of booster vaccination in the Peoples’ Republic of China. Programs and Abstracts of the 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan (2010).
   Google Scholar
• Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics118(3), 978–984 (2006).
   PubMed Web of Science ®Google Scholar
• Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaPIPV//PRP∼T booster at 18 to 19 months of age in Thai infants. Programs and Abstracts of the 6th Congress of the World Society for Pediatric Infectious Diseases. Buenos Aires, Argentina (2009).
   Google Scholar
• Zhang L, Prietsch SOM, Axelsson I, Halperin S. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev.1, CD001478 (2011).
   Google Scholar
• Jefferson T, Rudin M, Di Pietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine21(17–18), 2003–2014 (2003).
   PubMed Web of Science ®Google Scholar
• Desauziers E, Hessel L, Decker MD, Caro JJ, Liese JG. Systematic review of the effects of pertussis vaccines in children. Vaccine22(21–22), 2681–2684 (2004).
   Google Scholar
• Simondon F. Systematic review of the effects of pertussis vaccines in children. Vaccine22(23–24), 2965 (2004).
   Google Scholar
• Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med.334(6), 349–355 (1996).
   PubMed Web of Science ®Google Scholar
• Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill.12(1), 6 (2007).
   Google Scholar
• Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill.4(12), 128–129 (1999).
   Google Scholar
• Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr. Infect. Dis. J.26(9), 806–810 (2007).
   PubMed Web of Science ®Google Scholar
• Liese JG, Stojanov S, Peters A. Duration of efficacy after primary immunisation with Biken acellular pertussis vaccine (Tripedia). Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA (2003).
   Google Scholar
• Liese JG, Meschievitz CK, Harzer E et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J.16(11), 1038–1044 (1997).
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine24(33–34), 5960–5965 (2006).
   PubMedGoogle Scholar
• Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine22(27–28), 3530–3534 (2004).
   PubMed Web of Science ®Google Scholar
• Hviid A. Post-licensure epidemiology of childhood vaccination: the Danish experience. Expert Rev. Vaccines5(5), 641–649 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev. Vaccines4(2), 173–184 (2005).
   PubMed Web of Science ®Google Scholar
• Liese JG, Stojanov S, Froeschle J et al. Long term efficacy of Biken acellular pertussis vaccine (Tripedia). Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Toronto, Canada (2000).
   Google Scholar
• Bisgard KM, Rhodes P, Connelly BL et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998–2001. Pediatrics116(2), e285–e294 (2005).
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria–tetanus–pertussis containing acellular pertussis. Lancet354(9195), 2063–2068 (1999).
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers K, Kanra G, Roelants M et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b–tetanus toxoid conjugate (PRP–T) and diphtheria–tetanus–acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine17(7–8), 875–886 (1999).
   PubMedGoogle Scholar
• Greenberg DP, Doemland M, Bettinger JA et al. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type b pediatric combination vaccine and an adolescent–adult tetanus–diphtheria–acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr. Infect. Dis. J.28(6), 521–528 (2009).
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria–tetanus toxoids–acellular pertussis/Haemophilus influenzae type b and diphtheria–tetanus toxoids–acellular pertussis–inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J.23(10), 944–950 (2004).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, von Kries R, Hassenpflug B et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria–tetanus toxoids–acellular pertussis (–inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr. Infect. Dis. J.20(8), 767–774 (2001).
   PubMed Web of Science ®Google Scholar
• Cruces RP, Donoso FA, Camacho AJ, Llorente HM. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded programme on immunization in Chile. Rev. Chilena Infectol.23(1), 50–54 (2006).
   Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology113(2), 163–174 (2004).
   PubMed Web of Science ®Google Scholar
• Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill.11(3), E060302 (2006).
   Google Scholar
• Ladhani S, Heath PT, Slack MP et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin. Microbiol. Infect.16(7), 948–954 (2010).
   Google Scholar
• World Health Organization. Haemophilus influenzae type b conjugated vaccines – WHO position paper. Wkly Epidemiol. Rec.81(47), 445–452 (2006).
   PubMedGoogle Scholar
• Garpenholt O, Hugosson S, Fredlund H, Giesecke J, Olcen P. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatr.89(4), 471–474 (2000).
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost–effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine20(9–10), 1316–1330 (2002).
   PubMed Web of Science ®Google Scholar
• Iskedjian M, De Serres G, Einarson TR, Walker JH. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis. Vaccine28(3), 714–723 (2010).
   PubMed Web of Science ®Google Scholar
• Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP–T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP–T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, 6 months of age in Thai infants. Int. J. Infect. Dis.15, e249–e256 (2011).
   Google Scholar
• Lee SY, Hwang HS, Kim JH et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea. Vaccine29(8), 1551–1557 (2011).
   Google Scholar